# F5 (Factor V): Factor V Leiden R506Q Mutation, Activated Protein C Resistance, and Thrombophilia ## Key Takeaways - The **Factor V Leiden (FVL) mutation (c.1601G>A; p.Arg534Gln)** disrupts a critical cleavage site for Activated Protein C (APC), leading to **Activated Protein C Resistance (APCR)** and a significantly increased risk of venous thromboembolism (VTE). - FVL is the most prevalent inherited thrombophilia in individuals of European descent, with carrier frequencies around 5%, conferring a 3- to 7-fold increased VTE risk in heterozygotes and a 20- to 80-fold risk in homozygotes. - FV exhibits dual functionality: it acts as a cofactor in prothrombinase complex formation (procoagulant) and, when cleaved by APC, as a cofactor for APC in Factor VIIIa inactivation (anticoagulant); the FVL mutation impairs the latter. - Diagnosis of FVL typically involves functional APCR assays followed by genetic testing to confirm the specific c.1601G>A mutation, differentiating it from acquired APCR and other inherited thrombophilias like prothrombin G20210A. - Direct Oral Anticoagulants (DOACs) such as rivaroxaban, apixaban, and dabigatran are effective therapeutic options for FVL-associated thrombophilia as they target FXa or thrombin directly, independent of FV function. --- ## Executive Summary & Key Metadata The **F5** gene encodes coagulation Factor V (FV), a large, multi-domain glycoprotein that serves as an essential non-enzymatic cofactor in the prothrombinase complex. This complex converts prothrombin (Factor II) to thrombin (Factor IIa), a master serine protease that drives fibrin clot formation and platelet activation. Beyond its canonical procoagulant role, FV possesses an intrinsic anticoagulant function: when cleaved by activated Protein C (APC), it acts as a cofactor for the inactivation of Factor VIIIa (FVIIIa). This dual functionality places F5 at the fulcrum of hemostatic balance. The clinical significance of F5 is dominated by the **Factor V Leiden (FVL)** mutation, a single-nucleotide polymorphism (c.1601G>A, p.Arg534Gln in the mature protein; historically p.Arg506Gln) that abolishes one of three APC cleavage sites. This mutation results in **Activated Protein C Resistance (APCR)**, a hypercoagulable state that confers a 3- to 7-fold increased risk of venous thromboembolism (VTE) in heterozygotes and a 20- to 80-fold increased risk in homozygotes. FVL is the most common inherited thrombophilia in individuals of European descent, with a carrier frequency of approximately 5%. This reference manual provides a comprehensive, biophysically grounded analysis of F5, from its genomic architecture and protein domain organization to its complex regulatory networks, pathogenic mutations, and pharmacogenomic implications. | **Attribute** | **Specification** | | :--- | :--- | | **HGNC Symbol** | F5 | | **UniProt Accession** | P12259 | | **Representative PDB ID** | 1CZV (C2 domain) | | **Chromosomal Locus** | 1q24.2 | | **Primary Molecular Function** | Cofactor in prothrombinase complex; cofactor for APC in FVIIIa inactivation | | **Disease & Pathology Associations** | Factor V Leiden thrombophilia (OMIM #188055), Activated Protein C Resistance, Venous Thromboembolism, Recurrent Pregnancy Loss, Rare F5 deficiency (parahaemophilia) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Mapping and Gene Structure The F5 gene is located on the **long (q) arm of chromosome 1** at cytogenetic band **1q24.2**. The genomic coordinates (GRCh38/hg38) span approximately 80 kilobases (kb) from **chr1:169,511,951 to chr1:169,586,588** (reverse strand). The gene is composed of **25 exons** and **24 introns**, a structure that is highly conserved among the homologous coagulation factor genes, including F2 (prothrombin), F7, F9, F10, and PROS1 (Protein S). This shared architecture suggests a common evolutionary ancestry via ancient gene duplication events from a serine protease precursor. The mature FV mRNA transcript is approximately 6.9 kb in length, encoding a precursor protein of 2,224 amino acids. This precursor includes a 28-amino-acid signal peptide and a 28-amino-acid propeptide that are cleaved during post-translational processing. The mature, circulating single-chain FV molecule is 2,196 amino acids in length. ### 1.2 Promoter Architecture and Transcriptional Regulation The F5 promoter region lacks a canonical TATA box, a feature common to constitutively expressed "housekeeping" genes. Instead, transcription is initiated from multiple start sites within a GC-rich region. The core promoter contains several critical cis-acting elements: - **Sp1 (Specificity Protein 1) Binding Sites:** Multiple GC-box motifs (consensus sequence 5'-GGGGCGGGG-3') are located within 200 base pairs upstream of the transcription start site (TSS). Sp1 is a ubiquitous transcription factor that recruits the basal transcription machinery (TFIID) and is essential for basal F5 expression. - **HNF-4 (Hepatocyte Nuclear Factor 4) Elements:** A binding site for HNF-4, a master regulator of hepatocyte-specific gene expression, is located further upstream (approximately -300 to -400 bp). This element is critical for the high-level expression of F5 in the liver, the primary site of FV synthesis. - **C/EBP (CCAAT/Enhancer-Binding Protein) Sites:** Binding sites for C/EBPα and C/EBPβ contribute to the liver-specific expression and acute-phase regulation of F5. F5 is a mild positive acute-phase reactant, with plasma levels increasing in response to inflammation. - **Estrogen Response Elements (EREs):** Functional EREs have been identified in the F5 promoter. This explains the observed variation in FV plasma levels during pregnancy, oral contraceptive use, and hormone replacement therapy, all of which modulate thrombotic risk. ### 1.3 Enhancer Elements and Long-Range Regulation Chromatin conformation capture (Hi-C) studies have identified several putative enhancer regions within the F5 locus and its intergenic neighborhood. Notably, a distal enhancer element located approximately 20 kb upstream of the TSS has been shown to physically interact with the promoter in hepatocyte cell lines. This enhancer is enriched for histone modifications associated with active chromatin (H3K27ac and H3K4me1) and contains binding sites for the transcription factors FOXA1 and HNF-4. Single-nucleotide polymorphisms (SNPs) within this enhancer region have been associated with variations in plasma FV levels in genome-wide association studies (GWAS), although the causal variants and their mechanisms remain under active investigation. ### 1.4 Alternative Splicing and Isoforms While the primary transcript is constitutively spliced to produce the canonical full-length FV, several alternative splicing events have been documented: - **Alternative 3' UTR Usage:** The F5 gene has multiple polyadenylation signals, leading to transcripts with varying 3' untranslated region (UTR) lengths. These different 3' UTRs contain distinct microRNA (miRNA) binding sites, providing a layer of post-transcriptional regulation. For example, the longer 3' UTR isoform is predicted to be a target for miR-122, a liver-enriched miRNA, while the shorter isoform may evade this regulation. - **Exon Skipping Variants:** Low-abundance transcripts lacking exon 13 or exon 25 have been detected in RNA-seq datasets. Exon 13 encodes the large, heavily glycosylated B-domain, and its skipping would produce a truncated FV molecule. The functional significance of these minor isoforms is unclear, but they may represent a mechanism for generating FV variants with altered secretion or activity. - **Splice Site Variants:** A rare, alternatively spliced isoform that retains a portion of intron 12 has been reported. This isoform introduces a premature stop codon and is predicted to undergo nonsense-mediated decay (NMD), suggesting it is a byproduct of inefficient splicing rather than a functional protein. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization of the FV Precursor The FV protein is a modular protein composed of several distinct structural domains that are arranged in a linear fashion from the N-terminus to the C-terminus. The domain architecture is: **A1-A2-B-A3-C1-C2**. - **A1 Domain (Residues ~1-303):** The N-terminal A1 domain is homologous to the A domains of ceruloplasmin and the copper-binding proteins. It contains a high-affinity calcium-binding site and contributes to the binding interface with Factor Xa (FXa) in the prothrombinase complex. - **A2 Domain (Residues ~304-610):** The A2 domain is critical for procoagulant activity. It contains the binding site for FXa and is the location of the **Arg506** (R506) APC cleavage site. The A2 domain also harbors a transient interaction site for the tissue factor pathway inhibitor (TFPI). - **B Domain (Residues ~611-1545):** The B domain is a large, heavily N-glycosylated region that is unique to FV among the coagulation factors. It is not required for procoagulant activity and is cleaved and released during thrombin activation. The B domain functions as a "spacer" that prevents premature binding of FV to membranes and inhibits its interaction with FXa. It also contains a binding site for multimerin, a platelet α-granule protein. - **A3 Domain (Residues ~1546-1876):** The A3 domain, along with the C1 and C2 domains, forms the light chain of activated FV (FVa). The A3 domain contains a high-affinity binding site for FXa and contributes to the overall stability of the prothrombinase complex. - **C1 Domain (Residues ~1877-2037):** The C1 domain is a discoidin-type domain that contributes to membrane binding. It is essential for the proper orientation of FVa on the phospholipid surface. - **C2 Domain (Residues ~2038-2196):** The C2 domain is the primary membrane-binding module of FV. It contains a β-hairpin loop (the "spike") that inserts into the lipid bilayer, and several surface-exposed hydrophobic residues that interact with phosphatidylserine (PS). The C2 domain is the most structurally characterized region of FV, with several high-resolution crystal structures available (e.g., PDB: 1CZV). ### 2.2 Structural Biology of the C2 Domain (PDB: 1CZV) The representative PDB structure **1CZV** is the X-ray crystal structure of the C2 domain of human coagulation Factor Va, solved at 2.0 Å resolution. This structure provides atomic-level detail of the membrane-binding interface. The C2 domain folds into a compact β-sandwich composed of two anti-parallel β-sheets. The topology is a classic discoidin fold, consisting of eight β-strands (β1-β8) arranged in a "jelly-roll" motif. Three loops extend from the top of the domain (the "membrane-binding face"): loop 1 (between β3 and β4), loop 2 (between β5 and β6), and loop 3 (between β7 and β8). These loops are enriched in hydrophobic and aromatic residues (e.g., Trp, Phe, Leu) that penetrate the hydrophobic core of the phospholipid bilayer. A key feature is the presence of three solvent-exposed tryptophan residues (Trp2063, Trp2064, and Trp2065) that are critical for membrane insertion. The C2 domain also contains a calcium-binding site. While the C2 domain of FV does not require calcium for membrane binding (unlike the C2 domains of Protein Kinase C), the bound calcium ion stabilizes the structure and may modulate the affinity for PS-containing membranes. ### 2.3 Structural Basis of FV Activation and Inactivation FV circulates in plasma as a single-chain, relatively inactive procofactor. Its activation is a multi-step proteolytic process: 1. **Thrombin Cleavage:** Thrombin cleaves FV at three sites: Arg709, Arg1018, and Arg1545. Cleavage at Arg709 and Arg1018 releases the B-domain, while cleavage at Arg1545 separates the heavy chain (A1-A2) from the light chain (A3-C1-C2). The resulting FVa is a heterodimer held together by a calcium ion. 2. **FXa Cleavage:** FXa can also activate FV, albeit less efficiently than thrombin. FXa cleaves FV at Arg709, Arg1018, and Arg1545, but the order of cleavage differs, leading to a slightly different intermediate. The inactivation of FVa by APC is a critical regulatory step. APC cleaves FVa at three sites: **Arg306**, **Arg506**, and **Arg679**. Cleavage at Arg506 is the most rapid and occurs first. This cleavage is required for efficient exposure of the Arg306 site. Cleavage at Arg306 is the critical inactivating event, as it disrupts the A1-A2 domain interface, leading to the dissociation of the A2 domain and the complete loss of cofactor activity. Cleavage at Arg679 is a slower, secondary event that further degrades the molecule. The **Factor V Leiden (FVL) mutation** (p.Arg534Gln in the mature protein, corresponding to Arg506 in the conventional FVa numbering) abolishes the Arg506 cleavage site. This has two major consequences: - **Loss of APC-mediated cleavage at Arg506:** The primary APC cleavage site is lost, slowing the inactivation process. - **Impaired exposure of the Arg306 site:** Because Arg506 cleavage is required for efficient exposure of Arg306, the FVL mutation also impairs cleavage at Arg306. This results in a profound resistance to APC, with FVa:Leiden being inactivated approximately 10-fold more slowly than wild-type FVa. ### 2.4 Interactive 3D Visualization To explore the three-dimensional structure of the FV C2 domain and its membrane-binding interface, use the interactive visualizer: [Interactive 3D Protein Visualizer: Load F5 (PDB: 1CZV)](/tools/protein-structure-viewer?source=direct&pdbId=1CZV) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Coagulation Cascade and the Prothrombinase Complex FV is a central component of the coagulation cascade, a series of zymogen-to-serine protease conversions that culminate in the formation of a stable fibrin clot. FV functions as a critical non-enzymatic cofactor in the **prothrombinase complex**, which is the macromolecular machinery responsible for the explosive generation of thrombin. The prothrombinase complex is assembled on the surface of activated platelets and other cells that expose anionic phospholipids, primarily phosphatidylserine (PS). The complex consists of: - **Factor Xa (FXa):** The serine protease enzyme. - **Factor Va (FVa):** The protein cofactor (activated FV). - **Calcium Ions (Ca²⁺):** Required for the assembly and stability of the complex. - **Anionic Phospholipid Membrane:** Provides the surface for complex assembly. The assembly of the prothrombinase complex is a highly coordinated process. FVa binds to the membrane surface via its C1 and C2 domains. FXa binds to the membrane and to FVa, with the A2 and A3 domains of FVa providing the primary binding sites. The formation of this complex increases the catalytic efficiency of FXa-mediated prothrombin activation by **five orders of magnitude (10⁵-fold)** compared to FXa alone. This is achieved through two mechanisms: 1. **Substrate Channeling:** FVa binds prothrombin, bringing it into close proximity with the active site of FXa. 2. **Allosteric Modulation:** FVa induces a conformational change in FXa that optimizes its active site for prothrombin cleavage. ### 3.2 The Anticoagulant Function of FV In addition to its procoagulant role, FV has a distinct anticoagulant function. When FV is cleaved by APC at Arg506, it loses its procoagulant activity. However, the resulting molecule, termed **FVa:Leiden** or **APC-cleaved FV**, acquires a new function: it acts as a **cofactor for APC** in the inactivation of FVIIIa. FVIIIa is the cofactor for Factor IXa (FIXa) in the intrinsic tenase complex, which activates FX. By inactivating FVIIIa, APC downregulates the intrinsic pathway, reducing FXa generation and thus thrombin formation. This anticoagulant function of FV is dependent on the presence of Protein S (PROS1), which forms a membrane-bound complex with APC and FV. The dual role of FV is a classic example of a "moonlighting" protein, where a single protein performs two distinct functions depending on its post-translational modification state. The FVL mutation specifically abrogates the anticoagulant function of FV while preserving its procoagulant function, tipping the hemostatic balance toward thrombosis. ### 3.3 Protein-Protein Interaction Networks FV participates in a complex network of protein-protein interactions. Key interacting partners include: - **Factor Xa (FXa):** The central interaction in the prothrombinase complex. The binding interface involves the A2 and A3 domains of FVa. - **Prothrombin (FII):** The substrate of the prothrombinase complex. FVa binds prothrombin via its A1 and A3 domains. - **Activated Protein C (APC):** The key regulator of FVa. APC binds to FVa and cleaves it at Arg306, Arg506, and Arg679. - **Protein S (PROS1):** A cofactor for APC in the inactivation of FVa and FVIIIa. Protein S forms a 1:1 complex with APC and enhances its affinity for the membrane surface. - **Tissue Factor Pathway Inhibitor (TFPI):** TFPI inhibits the extrinsic pathway. TFPIα, a splice variant, binds to FVa and inhibits the prothrombinase complex. - **Multimerin (MMRN1):** A large, polymeric protein stored in platelet α-granules. Multimerin binds to FV and serves as a carrier protein, protecting it from premature activation. - **Annexin A5 (ANXA5):** An anticoagulant protein that binds to anionic phospholipid membranes. FV and Annexin A5 compete for the same membrane-binding sites, and the FVL mutation may alter this competition. ### 3.4 Regulatory Feedback Loops The coagulation system is tightly regulated by multiple positive and negative feedback loops. FV is involved in several of these: - **Positive Feedback via Thrombin:** Thrombin, the product of the prothrombinase complex, activates FV, generating more FVa, which in turn generates more thrombin. This creates a powerful positive feedback loop that drives the explosive generation of thrombin during clot formation. - **Negative Feedback via APC:** Thrombin, when bound to thrombomodulin on the endothelial cell surface, activates Protein C to APC. APC then inactivates FVa and FVIIIa, providing a negative feedback loop that limits clot formation. - **Regulation by TFPI:** TFPI, released from platelets and endothelial cells, inhibits the FXa-FVa complex, providing an additional layer of negative regulation. ```mermaid sequenceDiagram participant EC as "Endothelial Cell" participant PLT as "Activated Platelet" participant FV as "Factor V (Plasma)" participant FXa as "Factor Xa" participant FII as "Prothrombin (II)" participant FIIa as "Thrombin (IIa)" participant TM as "Thrombomodulin" participant PC as "Protein C" participant APC as "Activated Protein C" participant FVa as "Factor Va" participant FVL as "Factor Va:Leiden" Note over FV, FIIa: Procoagulant Pathway FV->>FIIa: Activated by Thrombin (cleavage at R709, R1018, R1545) FIIa->>FV: Generates FVa FVa->>FXa: Forms Prothrombinase Complex on PLT surface FXa->>FII: Converts to FIIa (Thrombin) FIIa->>FII: Positive Feedback (activates more FV) Note over EC, APC: Anticoagulant Pathway FIIa->>TM: Binds to Thrombomodulin on EC TM->>PC: Activates PC to APC APC->>FVa: Cleaves at R306, R506, R679 (Inactivation) APC->>FVL: Cleaves at R306, R679 only (Resistant to R506 cleavage) Note over FVL: FVL is inactivated ~10x slower, leading to hypercoagulability ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The Factor V Leiden (FVL) Mutation (c.1601G>A; p.Arg534Gln) The FVL mutation is a gain-of-function mutation that is the most common inherited risk factor for venous thrombosis. It is a single G-to-A transition at nucleotide 1601 in the F5 cDNA (c.1601G>A), resulting in the substitution of arginine (Arg) with glutamine (Gln) at position 534 of the mature protein (p.Arg534Gln). In the historical FVa numbering system, this is referred to as **Arg506Gln**. **Mechanism of APCR:** The mutation eliminates the primary APC cleavage site at Arg506. As described in Section 2.3, this leads to a 10-fold reduction in the rate of FVa inactivation by APC. The FVL variant also fails to acquire the anticoagulant cofactor function for APC-mediated FVIIIa inactivation. The combined effect is a pronounced hypercoagulable state. **Epidemiology:** FVL is found in approximately 5% of individuals of European descent, with a higher prevalence in certain populations (e.g., up to 15% in some Mediterranean regions). It is rare or absent in individuals of African, Asian, and Native American descent, suggesting a founder effect in a European ancestor. **Clinical Phenotype:** - **Heterozygotes:** 3- to 7-fold increased risk of VTE. - **Homozygotes:** 20- to 80-fold increased risk of VTE. - **Risk Modifiers:** The absolute risk of VTE in FVL carriers is influenced by other genetic and environmental factors, including the prothrombin G20210A mutation, oral contraceptive use, pregnancy, surgery, and immobility. - **Other Associations:** FVL has been associated with an increased risk of recurrent pregnancy loss, particularly in the second and third trimesters, likely due to placental thrombosis. It is also a risk factor for cerebral vein thrombosis. ### 4.2 The FV Cambridge Mutation (p.Arg306Thr) The FV Cambridge mutation is a rare mutation at the Arg306 APC cleavage site, where arginine is replaced by threonine (p.Arg306Thr). This mutation also causes APCR, but it is much less common than FVL. The clinical phenotype is similar to FVL, with an increased risk of VTE. However, the degree of APC resistance is generally less severe than that seen with FVL. ### 4.3 The FV Hong Kong Mutation (p.Arg306Gly) The FV Hong Kong mutation is another rare mutation at Arg306, where arginine is replaced by glycine (p.Arg306Gly). This mutation also causes APCR, but it is associated with a milder phenotype than FVL. Interestingly, the FV Hong Kong mutation does not appear to be a strong risk factor for VTE in all studies, suggesting that the loss of the Arg306 cleavage site alone may not be sufficient to cause a significant hypercoagulable state. ### 4.4 FV Liverpool (p.Ile359Thr) FV Liverpool is a rare mutation in the A2 domain (p.Ile359Thr) that is associated with a mild APCR phenotype. This mutation is located near the FXa binding site and is thought to alter the interaction between FVa and FXa, leading to reduced prothrombinase activity. The clinical significance of FV Liverpool is uncertain, and it may be a benign polymorphism. ### 4.5 FV Deficiency (Parahaemophilia) In contrast to the gain-of-function FVL mutation, loss-of-function mutations in F5 cause **Factor V deficiency** (parahaemophilia), a rare autosomal recessive bleeding disorder. These mutations are typically nonsense, frameshift, or splice-site mutations that result in a truncated or absent FV protein. The clinical phenotype is variable, ranging from mild bleeding (e.g., easy bruising, epistaxis) to severe hemorrhage. The severity of bleeding correlates with the residual FV activity level. ### 4.6 Combined FV and FVIII Deficiency Mutations in the genes encoding the ER-Golgi intermediate compartment (ERGIC) proteins, **LMAN1** (lectin, mannose-binding 1) and **MCFD2** (multiple coagulation factor deficiency 2), cause a combined deficiency of FV and FVIII. These proteins function as a cargo receptor complex that transports FV and FVIII from the ER to the Golgi apparatus. Mutations in LMAN1 or MCFD2 impair the secretion of both factors, leading to a mild-to-moderate bleeding disorder. ### 4.7 ClinVar Classification and Differential Diagnosis The clinical differential diagnosis for a patient presenting with VTE and suspected APCR includes: - **Factor V Leiden (FVL):** The most common cause of inherited APCR. - **Acquired APCR:** Can occur in the setting of pregnancy, oral contraceptive use, antiphospholipid syndrome (APS), and elevated FVIII levels. - **Prothrombin G20210A Mutation:** A common inherited thrombophilia that increases prothrombin levels. - **Protein C Deficiency:** A rare inherited thrombophilia. - **Protein S Deficiency:** A rare inherited thrombophilia. - **Antithrombin Deficiency:** A rare inherited thrombophilia. - **Antiphospholipid Syndrome (APS):** An acquired autoimmune disorder characterized by thrombotic events and the presence of antiphospholipid antibodies. The diagnosis of FVL is typically made using a functional APCR assay (e.g., the activated partial thromboplastin time (aPTT)-based assay with APC), followed by confirmatory genetic testing (PCR-based assay for the c.1601G>A mutation). --- ## 5. Host-Pathogen & Viral Interactions While F5 is not a primary target for viral oncoproteins in the same way as TP53 or RB1, there are several documented and theoretical interactions between pathogens and the coagulation system that involve FV. ### 5.1 Bacterial Pathogens - **Staphylococcus aureus:** S. aureus secretes several virulence factors that interact with the coagulation system. The most well-characterized is **coagulase**, which binds to prothrombin to form a complex called "staphylothrombin." This complex can directly cleave fibrinogen to fibrin, bypassing the need for FVa. However, S. aureus also produces **von Willebrand factor-binding protein (vWbp)**, which can bind to FV and activate it, potentially contributing to the formation of a protective fibrin shield around the bacteria. - **Streptococcus pyogenes:** Streptococcal pyrogenic exotoxin B (SpeB) is a cysteine protease that can degrade FV, potentially contributing to the hemorrhagic manifestations seen in severe streptococcal infections. - **Porphyromonas gingivalis:** This oral pathogen produces gingipains, cysteine proteases that can activate FV and FX, contributing to the hypercoagulable state associated with periodontitis. ### 5.2 Viral Pathogens - **Dengue Virus (DENV):** Severe dengue is characterized by a bleeding diathesis and coagulopathy. DENV non-structural protein 1 (NS1) has been shown to bind to prothrombin and induce its activation, but its interaction with FV is less clear. However, the systemic inflammatory response to DENV can lead to endothelial dysfunction and the consumption of coagulation factors, including FV. - **SARS-CoV-2 (COVID-19):** COVID-19 is associated with a high incidence of thrombotic complications, including VTE and arterial thrombosis. The mechanism is multifactorial, involving endothelial injury, inflammation, and the activation of the coagulation cascade. While FV levels are not directly targeted by the virus, the massive inflammatory response can lead to elevated FVIII and fibrinogen levels, and the formation of neutrophil extracellular traps (NETs) can activate the extrinsic pathway, leading to thrombin generation and FV consumption. ### 5.3 Parasitic Pathogens - **Plasmodium falciparum:** Severe malaria is associated with coagulopathy and thrombocytopenia. The parasite can induce the expression of tissue factor on endothelial cells, activating the extrinsic pathway and leading to the consumption of FV and other coagulation factors. --- ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 Direct Oral Anticoagulants (DOACs) The management of FVL-associated thrombophilia has been revolutionized by the introduction of DOACs. These agents directly target specific coagulation factors and do not require FV for their activity. - **Rivaroxaban, Apixaban, Edoxaban:** These are direct Factor Xa inhibitors. They bind to the active site of FXa, preventing it from cleaving prothrombin. Because they do not require FVa as a cofactor, they are effective in patients with FVL. - **Dabigatran:** This is a direct thrombin inhibitor. It binds to the active site of thrombin, preventing it from cleaving fibrinogen and activating platelets. It is also effective in FVL patients. **Pharmacogenomic Considerations:** The presence of FVL does not alter the pharmacokinetics or pharmacodynamics of DOACs. However, FVL status may influence the choice of anticoagulant and the duration of therapy. For example, a homozygous FVL patient with a first unprovoked VTE may be considered for indefinite anticoagulation, whereas a heterozygous FVL patient with a provoked VTE may only require 3-6 months of therapy. ### 6.2 Vitamin K Antagonists (VKAs) Warfarin and other VKAs are the traditional anticoagulants. They inhibit the enzyme vitamin K epoxide reductase (VKORC1), which is required for the γ-carboxylation of the vitamin K-dependent coagulation factors (FII, FVII, FIX, FX, and Protein C and S). FV is not a vitamin K-dependent protein, so its synthesis is not directly affected by VKAs. However, VKAs are effective in FVL patients because they reduce the levels of prothrombin and FX, which are required for the prothrombinase complex to function. **Pharmacogenomic Considerations:** The dosing of warfarin is highly variable and is influenced by polymorphisms in **CYP2C9** (which metabolizes warfarin) and **VKORC1** (the drug target). FVL status does not directly affect warfarin dosing, but it is a risk factor for warfarin-induced skin necrosis, a rare complication that occurs due to the rapid decline in Protein C levels. ### 6.3 Investigational Agents and Future Directions - **Anti-TFPI Agents:** Agents such as concizumab and marstacimab are monoclonal antibodies that inhibit TFPI. By blocking TFPI, these agents enhance the activity of the extrinsic pathway, promoting thrombin generation. They are being developed for the treatment of hemophilia, but they could theoretically be used to reverse the bleeding phenotype in FV deficiency. - **Fitusiran:** This is an investigational RNAi therapeutic that targets antithrombin (SERPINC1). By reducing antithrombin levels, fitusiran enhances thrombin generation. It is being developed for hemophilia but could have applications in FV deficiency. - **Gene Therapy:** Adeno-associated virus (AAV) vectors encoding the F5 cDNA are being explored for the treatment of FV deficiency. Preclinical studies in animal models have shown that AAV-mediated F5 gene transfer can restore hemostasis. This approach is not yet in clinical trials. ### 6.4 Targeting FV in Cancer FV is expressed in several cancer types, including pancreatic, colon, and breast cancer. Its role in cancer is complex and may involve both procoagulant and pro-metastatic functions. FV has been shown to promote tumor cell invasion and metastasis by activating the protease-activated receptor (PAR) signaling pathway. Targeting FV or its downstream effectors may represent a novel therapeutic strategy for certain cancers, but this is an area of active research with no approved agents. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of bioinformatic resources and database accessions for F5. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 2153 | Gene-specific information, genomic context, and links to related data. | | **Ensembl** | ENSG00000198734 | Genome annotation, transcripts, and variation data. | | **UniProt** | P12259 | Protein sequence, function, post-translational modifications, and domain architecture. | | **RCSB PDB** | 1CZV | Experimentally determined 3D structure of the C2 domain. | | **OMIM** | 188055 | Mendelian inheritance and disease associations (Factor V Leiden thrombophilia). | | **ClinVar** | 2153 | Clinically relevant variants and their pathogenicity classifications. | | **HGNC** | 3531 | Official gene symbol and nomenclature. | | **Gene Ontology (GO)** | GO:0005509 (calcium ion binding), GO:0007596 (blood coagulation), GO:0005515 (protein binding) | Functional annotations for molecular function, biological process, and cellular component. | | **STRING** | 9606.ENSP00000236390 | Protein-protein interaction networks. | | **BioGRID** | 108428 | Physical and genetic interactions. | | **PharmGKB** | PA142670 | Pharmacogenomic information and drug-gene interactions. | | **GTEx** | F5 | Tissue-specific gene expression data. | | **CCLE** | F5 | Cancer cell line expression and mutation data. | | **COSMIC** | F5 | Somatic mutations in cancer. | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References The following references are cited in the text. They represent a curated selection of the foundational and recent literature on F5, Factor V Leiden, and thrombophilia. [1] **Bertina, R. M., Koeleman, B. P., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994).** Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature*, 369(6475), 64-67. [https://doi.org/10.1038/369064a0](https://doi.org/10.1038/369064a0) [2] **Dahlbäck, B., & Hildebrand, B. (1994).** Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. *Proceedings of the National Academy of Sciences of the United States of America*, 91(4), 1396-1400. [https://doi.org/10.1073/pnas.91.4.1396](https://doi.org/10.1073/pnas.91.4.1396) [3] **Koster, T., Rosendaal, F. R., de Ronde, H., Briet, E., Vandenbroucke, J. P., & Bertina, R. M. (1993).** Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. *Lancet*, 342(8886-8887), 1503-1506. [https://doi.org/10.1016/S0140-6736(05)80081-9](https://doi.org/10.1016/S0140-6736(05)80081-9) [4] **Mann, K. G., & Kalafatis, M. (2003).** Factor V: a combination of Dr Jekyll and Mr Hyde. *Blood*, 101(1), 20-30. [https://doi.org/10.1182/blood-2002-01-0290](https://doi.org/10.1182/blood-2002-01-0290) [5] **Nicolaes, G. A., & Dahlbäck, B. (2002).** Factor V and thrombotic disease: description of a janus-faced protein. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 22(4), 530-538. [https://doi.org/10.1161/01.ATV.0000012665.51263.B7](https://doi.org/10.1161/01.ATV.0000012665.51263.B7) [6] **Segers, K., Dahlbäck, B., & Nicolaes, G. A. (2007).** Coagulation factor V and thrombophilia: background and mechanisms. *Th